RASSF1 and lung adenocarcinoma: This study comprehensively investigated the clinical utility of Shox2 and Rassf1a promoter methylation alongside driver mutations for molecular subtyping and stratification in 1027 lung adenocarcinoma (LUAD) patients.<h4>Methods</h4>This study included a cohort of 1027 LUAD patients who received treatment at the First Affiliated Hospital of Chongqing Medical University between January 2020 and August 2024.